AU5994099A - A novel ret-independent signaling pathway for gdnf - Google Patents
A novel ret-independent signaling pathway for gdnfInfo
- Publication number
- AU5994099A AU5994099A AU59940/99A AU5994099A AU5994099A AU 5994099 A AU5994099 A AU 5994099A AU 59940/99 A AU59940/99 A AU 59940/99A AU 5994099 A AU5994099 A AU 5994099A AU 5994099 A AU5994099 A AU 5994099A
- Authority
- AU
- Australia
- Prior art keywords
- gdnf
- signaling pathway
- independent signaling
- ret
- novel
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 101150082979 gdnf gene Proteins 0.000 title 1
- 230000019491 signal transduction Effects 0.000 title 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Neurology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Toxicology (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10264798P | 1998-10-01 | 1998-10-01 | |
| US60102647 | 1998-10-01 | ||
| PCT/IB1999/001681 WO2000020867A1 (en) | 1998-10-01 | 1999-10-01 | A novel ret-independent signaling pathway for gdnf |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU5994099A true AU5994099A (en) | 2000-04-26 |
Family
ID=22290937
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU59940/99A Abandoned AU5994099A (en) | 1998-10-01 | 1999-10-01 | A novel ret-independent signaling pathway for gdnf |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP1119772A1 (en) |
| JP (1) | JP2002526775A (en) |
| AU (1) | AU5994099A (en) |
| WO (1) | WO2000020867A1 (en) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9614871D0 (en) | 1996-07-15 | 1996-09-04 | Smithkline Beecham Plc | Compounds |
| US20020072051A1 (en) * | 2000-06-23 | 2002-06-13 | Bulawa Christine Ellen | Screen for identifying inhibitors of GPI anchoring |
| GB0102480D0 (en) * | 2001-01-31 | 2001-03-14 | Cyclacel Ltd | Marker |
| EP1925315A3 (en) * | 2001-02-27 | 2009-11-18 | Blanchette Rockefeller Neurosciences Institute | Alzheimer's disease diagnosis based on mitogen-activated protein kinase phosphorylation |
| JP4246495B2 (en) * | 2001-02-27 | 2009-04-02 | ブランシェット・ロックフェラー・ニューロサイエンスィズ・インスティテュート | Diagnosis of Alzheimer's disease based on mitogen-activated protein kinase phosphorylation |
| US20080070264A1 (en) * | 2003-03-05 | 2008-03-20 | Jpmorgan Chase Bank N.A. | Intracellular Signaling-Induced Ret-Independent Gdnf Receptor-Effected Morphological Changes |
| US20090029873A1 (en) | 2005-10-11 | 2009-01-29 | Blanchette Rockefeller Neurosciences Institute | Alzheimer's Disease-Specific Alterations of the Erk1/Erk2 Phosphorylation Ratio-Alzheimer's Disease-Specific Molecular Biomarkers (Adsmb) |
| EP2669386A1 (en) | 2008-07-28 | 2013-12-04 | Blanchette Rockefeller Neurosciences Institute | Stimulus-elicited genomic profile markers of alzheimer's disease |
| US8163800B2 (en) | 2008-07-28 | 2012-04-24 | Blanchette Rockefeller Neurosciences Institute | PKC-activating compounds for the treatment of neurodegenerative diseases |
| US8658134B2 (en) | 2009-10-02 | 2014-02-25 | Blanchette Rockefeller Neurosciences Institute | Fibroblast growth patterns for diagnosis of Alzheimer's disease |
| WO2013071281A1 (en) | 2011-11-13 | 2013-05-16 | Blanchette Rockefeller Neurosciences Institute | Esters of dcpla and methods of treatment using the same |
| SG11201807279QA (en) | 2016-03-31 | 2018-09-27 | Ngm Biopharmaceuticals Inc | Binding proteins and methods of use thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2000501924A (en) * | 1995-11-13 | 2000-02-22 | イバネズ,カルロス | Receptors for neuroglial factors derived from the glial cell line |
| DE69832797T2 (en) * | 1997-02-18 | 2006-08-17 | Genentech, Inc., South San Francisco | Neurturin RECEPTOR |
-
1999
- 1999-10-01 AU AU59940/99A patent/AU5994099A/en not_active Abandoned
- 1999-10-01 EP EP99970164A patent/EP1119772A1/en not_active Withdrawn
- 1999-10-01 WO PCT/IB1999/001681 patent/WO2000020867A1/en not_active Ceased
- 1999-10-01 JP JP2000574934A patent/JP2002526775A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2002526775A (en) | 2002-08-20 |
| WO2000020867A1 (en) | 2000-04-13 |
| EP1119772A1 (en) | 2001-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2977999A (en) | A lenticular illumination system | |
| AU4608099A (en) | 7-alkyl- and cycloalkyl-substituted imidazotriazinones | |
| AUPP422498A0 (en) | A lighting device | |
| AU4498199A (en) | A conveyor | |
| AU4392499A (en) | Switch | |
| AU2623899A (en) | Novel thiobenzamides | |
| AU2555499A (en) | A device for interlocking two parts | |
| AU2234699A (en) | Multiplex vgid | |
| AU5994099A (en) | A novel ret-independent signaling pathway for gdnf | |
| AU2350199A (en) | Novel aminoorganofunctionalsiloxanes | |
| AU3878499A (en) | A stress-follower circuit configuration | |
| AU4037699A (en) | Novel aryl-hydro naphthalenal kanamines | |
| AU5732599A (en) | Switch | |
| AU5851199A (en) | A conveyor system | |
| AU2636299A (en) | A lighting system | |
| AU4289199A (en) | Ptp package | |
| AU5432999A (en) | A plate conveyor | |
| AU2724799A (en) | Novel endo-xylogalacturonase | |
| AU4665499A (en) | A switching device | |
| AU4602999A (en) | A conveyor system | |
| AUPO783297A0 (en) | A link switch | |
| AU2137800A (en) | A switch | |
| AU4816199A (en) | A switching device | |
| AU4396299A (en) | Switch | |
| EP1144271A3 (en) | Packaging for a switch cabinet |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase |